Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

dard of care."

The Phase 3 study was designed to compare the safety and efficacy of motavizumab with that of Synagis, which was first launched by MedImmune in 1998, in reducing serious RSV disease in high-risk infants in the inpatient and outpatient settings. As defined in the study, infants who are at high risk for RSV include those who were born at 35 weeks gestation or less as well as those who have chronic lung disease (CLD) due to being born prematurely. The primary endpoint was to assess the incidence of RSV hospitalizations with motavizumab compared to Synagis. Motavizumab met the primary endpoint, demonstrating non-inferiority to Synagis with 26 percent fewer RSV hospitalizations in motavizumab-treated infants. The overall RSV attack rate was low in both treatment groups: 1.4 percent for infants who received motavizumab, compared with 1.9 percent for those who received Synagis [RR: 0.740, 95 percent CI: (0.503, 1.083)]. The p-value for non-inferiority was p<0.01, demonstrating a significant finding.

Analysis of the data also showed that motavizumab reduced the incidence of RSV-specific medically attended outpatient LRIs (the study's RSV-related secondary endpoint) by approximately 50 percent compared with Synagis. The overall RSV-specific medically attended LRI rate was 2.0 percent for infants who received motavizumab compared with 3.9 percent for those who received Synagis (p<0.01). There were no significant differences in other non-RSV- specific endpoints.

"I am very pleased with the study results for motavizumab," said Xavier Carbonell, M.D., Ph.D., lead study author, chairman of neonatology, Barcelona Hospital Clinic, and vice president, Spanish Neonatal Society. "As a practicing neonatologist, I look forward to the potential to use this next- generation antibody to help reduce RSV-related hospitalizations and LRIs in the outpatient setting."

Data from this trial demonstrate that both study drugs were well tolerated. The incid
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/31/2014)... July 31, 2014  Genomic Health, Inc. (Nasdaq: ... conference call and webcast on Thursday, August 7 at 4:30 ... results.  The call and webcast will follow the release of ... Conference Call Details To access the live conference call on ... dial (877) 303-7208 from the United States ...
(Date:7/31/2014)... WASHINGTON , July 31, 2014  CVS/pharmacy ... first pharmacy in the nation to earn the ... health care accreditation organization that establishes quality standards ... Longs Drug Store locations nationwide have earned this ... accreditation programs. Its Community Pharmacy Accreditation Program was ...
(Date:7/31/2014)...  Celsion Corporation (NASDAQ: CLSN ) announced ... to discuss its second quarter 2014 financial results at ... participate in the call, interested parties may dial 1-800-533-7954 ... and ask for the Celsion Corporation Second Quarter 2014 ... before the call is scheduled to begin. The call ...
Breaking Medicine Technology:Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 3Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 4CVS/pharmacy Earns First-Ever Community Pharmacy Accreditation from URAC 2CVS/pharmacy Earns First-Ever Community Pharmacy Accreditation from URAC 3Celsion Corporation to Hold Second Quarter 2014 Financial Results 2
... Loss, Non-Inferiority in Target Vessel Failure and Low Rates of MACE ... ... PARK, Ill., April 22 A study published,in today,s Journal of ... Everolimus Eluting Coronary Stent System,in patients with coronary artery disease resulted ...
... Data For Presentation At ASCO 2008, LONDON ... a wide range of new data at the ... Chicago starting Friday, May,30th. The data cover a ... treatment and supportive care of cancer,patients. At this ...
Cached Medicine Technology:Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 2Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 3Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 4Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 5GlaxoSmithKline Reports Further Progress of Oncology Portfolio 2GlaxoSmithKline Reports Further Progress of Oncology Portfolio 3GlaxoSmithKline Reports Further Progress of Oncology Portfolio 4GlaxoSmithKline Reports Further Progress of Oncology Portfolio 5GlaxoSmithKline Reports Further Progress of Oncology Portfolio 6GlaxoSmithKline Reports Further Progress of Oncology Portfolio 7
(Date:7/31/2014)... (PRWEB) July 31, 2014 Women in ... take charge of their financial future. The Independent ... has opened registration for 6 upcoming Los Angeles area ... for women, and with input from Kim Kiyosaki, a ... It’s Rising Time) who is passionate about women’s financial ...
(Date:7/31/2014)... 31, 2014 Dr. Andrew Lian-Jie Li ... of Dermatology, fellowship trained Mohs surgeon that has been ... , After extensive dermatology research training at the National ... Li completed his internship in internal medicine at the ... Pennsylvania in Philadelphia. Dr. Li pursued further training in ...
(Date:7/31/2014)... Las Vegas, NV (PRWEB) July 31, 2014 ... commitment to helping independent pharmacies enhance patient care ... on compliance and medication adherence. The first of ... during the opening of ThoughtSpot 2014, Good Neighbor ... Centers for Medicare and Medicaid Services (CMS) Star ...
(Date:7/31/2014)... York (PRWEB) July 31, 2014 ... as Bernstein Liebhard LLP notes that Johnson & ... plans to voluntarily remove its power morcellators ( ... report from Bloomberg.com, the company said it decided ... associated with the devices remain uncertain.* , “In ...
(Date:7/31/2014)... Model moms are believers. PBS has a ... in the field have grown exponentially in the last two ... industry, there are associated myths that need to be busted. ... Frontier Nursing University . Celebrating 75 years in 2014, Frontier ... in the nation. “Frontier is changing the face of healthcare ...
Breaking Medicine News(10 mins):Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2Health News:NJ Top Docs Proudly Presents Approved Provider, Dr. Andrew Li of Warren Skin Care Center 2Health News:Good Neighbor Pharmacy Reinforces Commitment to Helping Enhance Patient Care 2Health News:Good Neighbor Pharmacy Reinforces Commitment to Helping Enhance Patient Care 3Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 2Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 3Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 4Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 5
... for the skin. The skin absorbs almost 5lb of chemical ... makeup. Mr. Richard Bence, a biochemist, told that this is ... into the bloodstream. ,Women, across the globe, use a vast ... use is leading to a chemical pile up in their bodies. ...
... are a $22 billion industry in the US. ... addressing concerns over the ingredients that go into the making ... that it is phasing in a new rule making for ... ,Frequently it has been pointed out that in many ...
... claimed that they can trace marijuana to its roots, and ... was grown indoors or out . ,According to Matthew ... have something more precise in the near future that could ... marijuana is grown. ,"There are scientists already doing this ...
... Purdue University researchers have begun the first phase of human ... designed in-house. ,The drug is based on ... university. The researchers say that it may help intercept and ... of people suffer from this devastating disease and treatment options ...
... (ERS) published a new statement on pulmonary function testing ... American Journal of Respiratory and Critical Care Medicine, ... function testing in children aged 2 to 6. ... Stephanie Davis, M.D., co-chair of the 33-member ATS/ERS working ...
... the country that would become "launch pads" for the ... Manmohan Singh announced here Friday. ,"This expansion is ... high-quality education across the country. These universities should focus ... the top institutions in the world," the prime minister ...
Cached Medicine News:Health News:Make Up Unhealthy for Skin 2Health News:US FDA Wants Vitamin Manufacturers to Test All Ingredients 2Health News:Now, It's Possible to Trace Marijuana to Its Roots 2Health News:Ex-IITian-designed Alzheimer's Drug's Human Clinical Trials Begin 2Health News:India to Have 30 World-class Universities Across the Country: PM 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: